Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India · Delayed Price · Currency is INR 1,197.50
-10.90 (-0.90%)
Last updated: Oct 22, 2026, 3:29 PM IST
Symbiotec Pharmalab Revenue
Symbiotec Pharmalab had revenue of 2.18B INR in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to 8.84B. In the fiscal year ending March 31, 2026, Symbiotec Pharmalab had annual revenue of 8.69B with 15.65% growth. That makes Symbiotec Pharmalab the 23,199th largest company in the world by revenue and 1,369th in India.
Revenue (ttm)
8.84B
Revenue Growth
+15.65%
P/S Ratio
8.70
Revenue / Employee
4.62M
Employees
1,915
Market Cap
76.95B
Revenue by Geography
- India 2.87B 33.0%
- Europe 2.53B 29.1%
- Rest of World 2.16B 24.8%
- United States 1.14B 13.1%
Fiscal year ended Mar 31, 2026 See the full Symbiotec Pharmalab breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.69B | 1.18B | 15.65% |
| Mar 31, 2025 | 7.52B | 353.07M | 4.93% |
| Mar 31, 2024 | 7.16B | 1.50B | 26.43% |
| Mar 31, 2023 | 5.67B | -1.15B | -16.91% |
| Mar 31, 2022 | 6.82B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 25.24B |
| Neuland Laboratories | 23.72B |
| Shilpa Medicare | 16.83B |
| Bajaj HealthCare | 6.28B |
| NGL Fine-Chem | 5.36B |
| Aarey Drugs & Pharmaceuticals | 4.15B |
| Gujarat Themis Biosyn | 1.74B |
| Influx Healthtech | 1.47B |